You searched for: neurotoxin (Engelska - Slovenska)

acrylamide is a neurotoxin.
najnižja vrednost ph tega območja je približno 8.

clostridium botulinum neurotoxin type a
nevrotoksin bakterije clostridium botulinum tipa a

the effect of administering different botulinum neurotoxin serotypes concurrently is unknown.
učinek sočasne uporabe različnih serotipov nevrotoksina botulina ni znan.

hypersensitivity to the active substance botulinum neurotoxin type a or to any of the excipients.
preobčutljivosti za zdravilno učinkovino, botulinski nevrotoksin tipa a ali katero koli pomožno snov.

the clinical effects of botulinum neurotoxin type a can increase or decrease by repeated injections.
klinični učinek botulinskega nevrotoksina tipa a se lahko s ponavljajočim se injiciranjem poveča ali zmanjša.

diplopia may develop as a result of botulinum neurotoxin type a diffusion into the inferior oblique.
kot posledica difuzije botulinskega nevrotoksina tipa a v inferiorno poševno zrklno mišico se lahko razvije diplopija.

botulinum neurotoxin type a blocks cholinergic transmission at the neuromuscular junction by inhibiting the release of acetylcholine.
botulinski nevrotoksin tipa a blokira holinergični prenos na nevromuskularnih ploščicah, tako da zavira sproščanje acetilholina.

tetanus is an acute, often fatal disease caused by the neurotoxin of the bacterium clostridium tetani.
tetanus je akutna bolezen, ki ima pogosto smrten izid, povzroča pa jo nevrotoksin bakterije clostridium tetani.

tetanus is an acute, often fatal disease caused by a neurotoxin produced by the bacterium clostridium tetani.
tetanus je akutna bolezen, ki ima pogosto smrten izid, povzroča pa jo nevrotoksin, ki ga proizvaja bakterija clostridium tetani.

1 vial contains 100 ld50 units of clostridium botulinum neurotoxin type a (150kd), free of complexing proteins
1 viala vsebuje 100 enot ld50 nevrotoksina bakterije clostridium botulinum tipa a (150 kd), brez beljakovin, ki tvorijo komplekse.

clinical verification of the neurotoxin effect on the injected muscle: e. g. an electromyographic investigation in a specialised facility
17 Če v enem mesecu od prvega injiciranja ni učinkov zdravljenja, je treba uporabiti naslednje ukrepe:

xeomin100 ld50 units powder for solution for injection clostridium botulinum neurotoxin type a (150 kd), free of complexing proteins
xeomin 100 enot ld50 prašek za raztopino za injiciranje nevrotoksin bakterije clostridium botulinum tipa a (150 kd), brez beljakovin, ki tvorijo komplekse

blepharospasm because of the anticholinergic effect of botulinum neurotoxin type a, xeomin should be used with caution in patients at risk of developing an angle closure glaucoma.
blefarospazem zaradi antiholinergičnega učinka botulinskega toksina tipa a je treba zdravilo xeomin pri bolnikih, pri katerih obstaja tveganje za nastanek glavkoma z zaprtim zakotjem, uporabljati previdno.

clinical data botox and xeomin are different drug substances in terms of clostridial protein content, although both contain the same 150 kda neurotoxin, which is the actual active substance.
klinični podatki botox in xeomin sta z vidika vsebnosti proteinov clostridium različni zdravili, čeprav obe vsebujeta isti 150 kda nevrotoksin, ki predstavlja dejansko zdravilno učinkovino.

the mechanism of action by which botulinum neurotoxin type a exerts its effects on cholinergic nerve terminals can be described by a three-step sequential process which includes the following steps:
mehanizem delovanja botulinskega nevrotoksina tipa a na holinergične živčne končiče poteka v treh zaporednih korakih:

theoretically, the effect of botulinum neurotoxin may be potentiated by aminoglycoside antibiotics or other medicinal products that interfere with neuromuscular transmission e. g. tubocurarine-type muscle relaxants.
19 teoretično se lahko učinek botulinskega nevrotoksina okrepi z aminoglikozidnimi antibiotiki ali drugimi zdravili, ki ovirajo nevromuskulaturni prenos, npr. tubokuraninskimi mišičnimi relaksanti.

if you are allergic (hypersensitive) to botulinum neurotoxin type a or any of the other ingredients of xeomin (see section 6 “ further information”)
če ste alergični na (preobčutljivi za) botulinski nevrotoksin tipa a ali katero koli sestavino zdravila xeomin (glejte poglavje 6 “ dodatne informacije ”),

botox has a protein content of 5 ng/ 100u, i. e. the 150 kda neurotoxin and non-effective complexing proteins, and quickly dissociates into the neurotoxin and the complexing proteins after administration.
zdravilo botox ima vsebnost beljakovin 5 ng/ 100 e, tj.